Romans 12:19
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
what about the new eye's looking to invest.. your complaining about it is more of a waste of time.
Coronavirus deaths in kids echoes toll in adults, CDC says http://www.fox61.com/article/news/health/coronavirus/cdc-coronavirus-deaths-in-kids/507-5f50e8d4-3369-432f-a4e0-ce6362114e3c via @FOX61News
Coronavirus deaths in kids echoes toll in adults, CDC says http://www.fox61.com/article/news/health/coronavirus/cdc-coronavirus-deaths-in-kids/507-5f50e8d4-3369-432f-a4e0-ce6362114e3c via @FOX61News
Looking good
..stock price? I thought you were going to say Welcome to The Greatest Show on Earth and bring out some Lions and Elephants.. no guess for me. expectation frustrates, I'll take it as it comes..
SWX: RLF
0.49 CHF +0.0020 (0.41%)
Sep 14, 5:08 PM
307,930 new cases in 24 hours / The World Health Organization (WHO) has recorded a record one-day rise in the number of new coronavirus infections, with 307,930 reported over 24 hours.
WHO reports record daily rise in coronavirus cases http://a.msn.com/01/en-us/BB18ZT9z?ocid=st
307,930 new cases in 24 hours / The World Health Organization (WHO) has recorded a record one-day rise in the number of new coronavirus infections, with 307,930 reported over 24 hours.
WHO reports record daily rise in coronavirus cases http://a.msn.com/01/en-us/BB18ZT9z?ocid=st
I don't know.. maybe we should just move forward and leave that alone IMO beside we have the trial results coming which holds more weight with the powers that be..
Had to look that up... specious
['speSH?s]
ADJECTIVE
superficially plausible, but actually wrong.
"a specious argument"
misleading in appearance, especially misleadingly attractive.
"the music trade gives Golden Oldies a specious appearance of novelty"
Absolutely
"Just Matter of Time" ..yes.
lies.. people getting fed crap in other Countries..
Relief Therapeutics Share: The Big Mistake!
By Frank Holbaum -13 September 2020
861 Stern2 Sterne3 Sterne4 Sterne5 Sterne
Relief Therapeutics posted another price premium in late trading in the U.S. on Friday. The stock has risen to more than 50 US cents, giving some hope. At around 8 million shares, the trading volume was roughly equivalent to what was also implemented in Switzerland. The stock lost there. The big mistake: The company is expected to move further downwards in the coming sessions.
No cure in sight
The reason for the price gains was the hope that relief therapeutics would be able to develop an active ingredient for healing in the corona pandemic. However, this is unlikely at present. There are no reports that even a breakthrough has been made here.
Should investors sell immediately? Or is it worth getting started at Relief Therapeutics?
As a result, the market has reacted again in recent weeks with a subdued course after a massive price break. Over the past five days, it has gone down more markedly, with a discount of –3.5%. Now, however, speculation is under scrutiny:
With a trading volume of less than 10 million euros per day, the stock is a classic penny stock. From a chart-technical point of view, the discount of the past few days is not yet dramatic, but there is no support with high volumes. In this respect, it may be highly questionable whether and if for how long Relief Therapeutics can remain in the upward movement.
A new or further outbreak would only be expected if new findings were actually found or if information about it was disseminated in advance. A new speculation, on the other hand, is not apparent from the current reports and also from the price movements. In this respect, the signs are not particularly good, at least in the short term.
Buy, Hold or Sell – Your Relief Therapeutics Analysis of September 13 provides the answer:
How will Relief Therapeutics develop now? Is your money safe in this stock? The answers to these questions and why you need to act now can be found in the latest Relief Therapeutics Stock analysis.
Relief Therapeutics: Buy or sell? (read more here)
https://www.finanztrends.info/relief-therapeutics-aktie-der-grosse-irrtum/
---------------
maybe some of the Swiss are falling for these BS articles.. ?
States plow forward with pot, with or without Congress http://a.msn.com/01/en-us/BB18Z3DT?ocid=st
Why are clinical trials of new drugs so expensive?
Clinical trials form a vital part of drug development. Throughout the process, physicians test new drugs on carefully selected patient cohorts to establish the safety, efficacy and clinical benefits of these drugs.
https://www.srgtalent.com/blog/why-are-clinical-trials-of-new-drugs-so-expensive
Why are clinical trials of new drugs so expensive?
Clinical trials form a vital part of drug development. Throughout the process, physicians test new drugs on carefully selected patient cohorts to establish the safety, efficacy and clinical benefits of these drugs.
https://www.srgtalent.com/blog/why-are-clinical-trials-of-new-drugs-so-expensive
Summer parties, teacher shortages push suburban schools to scrap COVID reopening plans http://a.msn.com/01/en-us/BB18YC43?ocid=st
..could those trades also be shares they're putting back .. you know the many 100 - 500 and 2000 block sells that they use throughout the day to keep the price down?
Yes, cases are picking up and younger people dying.. I think the timelines set for therapeutics will accelerate.
$RLFTF Javitt Transcribed... CEO Roundtable with Dr. Javitt on Sept 10, 2020
by Uncle Gee Gee
-----------------------
I've transcribed the video and found many little nuggets of detail worth reading through.
For your weekend enjoyment...
CEO Roundtable with Dr. Javitt on Sept 10, 2020
15:55 Write - Jonathan, how does a clinical stage small molecule company that’s develop CNS-oriented therapeutics get involved in treating respiratory failure in Covid-19? I just want to understand how that happens.
16:20 Javitt - Well you know it’s like one of those extraordinary accidents, but some people say chance favors the prepared mind. And believe it or not vasoactive intestinal peptide, which is the active ingredient we’re working with, is a neuro endocrine peptide. And we were originally thinking about this in the CNS context. Then one of our investors came along and said well we have this company over in Switzerland that’s been thinking about this from a Covid-19 perspective. And sure enough it turns out that when Professor Sammy Said, who spent his whole life developing this peptide, really understood what it did, even though it was first identified in the intestine, which is why it has this funny name, 70% of the VIP in the body is in the lung, and it seems to have one critical function in the lung, which is to protect the Type II Alveolar Cells. Most people never heard of the Type II Alveolar Cell. In fact when I was in medical school, I don’t even think we knew that there were Type I and Type II cells. But this rare cell (there’s only about 5% of all the cells that line the lung), is the cell that is critical where the flow of oxygen’s coming in to the blood stream. And it makes the surfactant that lines the lung. Without the surfactant, the lung can’t transmit oxygen. And this funny virus, this virus that humanity’s never really encountered before SARS came along, attacks that one cell. It’s almost like hitting a needle in a haystack. And it attacks that one cell because that one cell happens to have ACE II receptors on its surface. So those funny spikes you see on the virus, they bind right to that receptor just like a key fitting a lock and the cell says come on inside, and as soon as the virus is inside the cell, it starts to make millions of copies of itself, it starts to let inflammatory cytokines loose all over the body, it ruptures the cell and it shuts down surfactant production, so all of a sudden, people who don’t even look that sick, have no oxygen in the blood. They can’t walk from their bed to the bathroom without falling down on the floor.
And… what we learned, what we expected is this would be a potent anti-cytokine. We thought we’d do a great job at blocking cytokines, and a great job at increasing surfactant production. And then lo and behold, a group of people we never heard of, at the Oswaldo Cruz Institute in Rio de Janeiro, reached out to us and said, you know that molecule you’re working with… here’s the data that shows that it blocks the replication of the SARS virus in human lung cells. So it was (inaudible 19:13) for us. It was, now we see why we’re seeing extraordinarily rapid recovery in the clinic. When we went into the clinic with this drug, and we literally went from paper files (because nobody has used this drug in humans for 10 years), from paper files to freshly formulated drug, with a fresh FDA certificate of analysis in human beings, in 10 weeks. When we went into the clinic, we expected to see an anti-inflammatory effect. We expected to see some of the same effects that Dr. Said saw in 2005 when he used this drug against Acute Respiratory Distress Syndrome, caused by sepsis, where seven out of eight people walked out of the ICU alive, when you would expect at least five of them to have died. What we didn’t expect to see, was chest x-rays clearing in 3 and 4 days. We didn’t expect to see that some of the early results we reported, where uh, you know out of the first 21 patients we treated outside our clinical trial, they were too sick to get into our clinical trial, 11 of those people have done very well, and 19 out of those 21 people have survived 28 days, which is the cutoff that NIH generally uses, 28-day survival is a critical endpoint. So we’ve been very surprised by the magnitude of response we’ve seen in the open label studies, and now we’re about a month away from the first unblinded look at the Phase III randomized control data. So, you know, we’re wondering, are we seeing the world’s biggest placebo effect, or are we really on to something.
21:15 Write - Rob Write asked a question regarding the company’s core competency and whether there was any internal struggle about pivoting on their strategy.
21:45 Javitt - I think the thing that is core to our company we’re just not afraid of anything. And we’re especially not afraid to go to FDA and say please help us break the rules. I mean there was 10 weeks from paper files to drug in the clinic in patients. Well that’s never going to happen through traditional GMP manufacturing, through standing up a fill and finish manufacturer. Those people take 6 months just to get their machines tuned up. So we went to FDA and said: You’ve got this list of 50 formulating pharmacies that you say passed your inspection. These 50 tiny little pharmacies that you say are safe, you didn’t shut them down, you actually certified them as formulating pharmacies, how about we make this drug in one of those formulating pharmacies?
We’re literally making this drug by hand in order to be able to get it into a Phase III trial overnight. And FDA was willing to help us break those rules, or at least willing to waive those rules, and recognize that if we’re facing the worst public health crisis in the last 100 years, we’ve got to be willing to do things in new ways, otherwise, we’re just dinosaurs looking at that asteroid coming closer and closer.
23:09 Write - I’m curious Jonathan about the formulating pharmacies idea. That’s kind of uh just an interesting approach, and I imagine your also trying to figure out how to do the scale up as you’re doing it now and it well in advance so things can continue to progress. Can you tell us a little bit about where the idea came about?
23:24 Javitt – Oh we’re hahaha we’re not going to try that one twice. So we’ve actually just signed a contract with one of those fill and finish manufacturers that we’re hoping to announce very shortly, uh and they’re actually the largest manufacturer of sterile inhaled drug in the world. Although our clinical trials with intravenous drug, we’ve already announced the trail that we intend to start quite shortly with an inhaled version of this drug, for people not with critical Covid-19, not the people who were on ventilators that we’re treating right now, but people with earlier stage disease in the hopes of keeping them from going on ventilators.
So we’ve started out the very non-traditional way, and we’re morphing as quickly as we possibly can to sort of rock-solid traditional scalability.
31:10 Write - Rob Write asks the panel about how to remain agile in an environment where FDA is getting political pressure to accelerate development, while also getting pressure from executives to base approvals on science, not political manipulation.
31:43 Javitt - Well I haven’t seen any evidence that FDA is being less stringent with people, they’re certainly not being less stringent with us. What they’re doing is being a lot quicker at being stringent. So, meeting requests that used to take 60 and 90 days, all of a sudden take, 60 and 90 hours to be answered. And when you send them a question, they’re turning around the answer in 48 hours. In 30 years of knowing the FDA, I’ve never seen anything like this. I’ve gotten emails from FDA scientists that they wrote and sent at two in the morning. So, it’s one thing to relax the standards, and it’s another to step up and apply those standards as quickly as you possibly can for the benefit of humanity.
32:42 Write - Rob Write continues the conversation about the FDA working long hard hours, despite typical hiring gaps.
33:23 Javitt - Well part of what’s changed things, and we really have Scott Gottlieb to thank for this, is the 21st Century Cures Act that was passed I guess it’s now, three and a half years ago, and then we have Scott come in as commissioner, being the first commissioner to really implement that act, and congress finally gave the commissioner of the FDA the tools that were needed to attract the best and the brightest, which included some real salaries. All of a sudden, FDA is able to pay salaries that certainly are not at the top of industry scale, they’re not paying anybody millions of dollars, but they’re able to pay somebody enough of a salary to leave a major pharmaceutical company, and take a job as a regulatory scientist to proving drugs, and without that, the agency can’t work.
36:57 Javitt - If you’ve got a, just a couple minutes, I’d love to go back to something Brian said earlier, when he said, you know, we’re focusing on the patients with most severe disease. And it’s certainly true that that’s where we started, uh because those are the patients who are dying by the hundreds and thousands, but, there really is a platform play that I think needs to be thought about by more people than just us. The whole story of this virus is its ability to enter very specific cells in the (upper thellia???). It only enters those weird cells that have ACE II surface receptors, and that’s mostly a couple of cells in the nasal zone, because that’s where the virus seems to get going, and then it goes down to the lung and it enters these Alveolar Type II Cells. And if you can stop that process, then the SARS Cov 2 virus is either asymptomatic or nothing more than a mild cold. And people are talking about, grand platforms and systemic approaches and all of that, but in fact, this virus is doing us so much harm, because its figured out how to hit a needle in a haystack, and the more we can focus on that needle, the more we can focus on how does the virus gets into that cell and how do we stop it in that cell. It may be that we never have a vaccine. I hope we do, but so far, as long as I’ve lived, we’ve never had a vaccine that’s able to stop an RNA virus. And yet similarly with pneumonia, we invented penicillin in the 1920’s, and it was 65 or 70 years before we had a vaccine against Pneumococcus, but we did a great job of keeping people from dying of pneumonia over those 70 years, just because we were able to interdict the process. So I truly hope we wind up with vaccines. I truly hope we wind up with sort of mobile immunologic approaches to this virus, but in fact there’s some very focused things we could be doing that we’re not doing to deal with this particular family of viruses and their determination to eradicate the human race.
50:16 Write - Rob Write asks for final parting thoughts.
50:20 Javitt - I think the most important thing is not to be afraid to break the rules. Yet the pharmaceutical industry is very tradition-bound. People know they’re supposed to do things a certain way, and that’s good, because by and large its kept the American pharmaceutical industry from having some of the crises that other pharmaceutical industries around the world haven’t had, but this is a time where we have to break the rules. I once watched a major pharmaceutical company lose $2 billion of revenue that their shareholders would have enjoyed having, because the person, and it was only one person, responsible for making clinical trial supplies, couldn’t figure out how to make clinical trials supplies for an existing drug, about a 15 year old drug, within 24 months in order to satisfy the FDA’s request for a pediatric trial that would have given them a 6 month patent extension, because you know, making boxes of clinical trial supplies for 150 people was just too much work. If we don’t break the rules, and if we don’t break the rules consciously every day, we’re going to lose many more people to this pandemic than we need to.
I really believe Revive and Relief will break through together on approval.. IMO
Fauci says US won't get back to normal until late 2021 http://a.msn.com/01/en-us/BB18WHQa?ocid=st
$RLFTF Here's the pre-print for the 19/21
https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3665228
And the pre-print for the 6/6
https://www.preprints.org/manuscript/202008.0640/v1
And the Clinical Trials...
List: https://clinicaltrials.gov/ct2/results?term=Aviptadil&draw=2&rank=1#rowId0
• Clinical Trial NCT04311697 – The initial clinical trial underway to test intravenously administered drug. Approximately 86 out of 122 patients have been recruited as of Aug 12, and the company’s data committee will begin reviewing the cases once they reach 102 patients. From there, they will present findings to the FDA. Speculation: Review could begin this week of 8/24; however, official publication of results could take several more weeks, but likely before October, due to Javitt’s comments about being able to ramp up production by October.
• Clinical Trial NCT04453839 – The FDA-approved Expanded Access program for treating patients who are too sick for clinical trials.
• Expanded Access results were released in a “pre-print” document, showing 19 of 21 patients have survived. These are the sickest of the sick (ICU, ventilators, ECMO patients). The pre-print is under peer review & expected to be officially released in the coming weeks.
• Clinical Trial NCT04360096 – A study of 288 patients to test an inhaler-version of RLF-100, intended to ultimately be used for in-home treatments. Estimated completion of trial is November 30th. According to Dr. Javitt: “We expect that half the people we enroll in our inhaled study are going to be people who are outpatients.”
• Clinical Trial NCT04536350 – A study of 80 patients in Switzerland to test an inhaler-version of RLF-100 as a preventative treatment.
- Uncle Gee DD (copy)
Dr Javitt specifically said in that video posted on Twitter at the 23.25 mark... that they have signed a contract with the largest inhaled manufacturer of drug and hope to announce it very soon!
What's Happening On The Front Lines of COVID-19: A CEO Roundtable On Technologies In Development For The Current Pandemic https://www.lifescienceleader.com/doc/what-s-happening-on-the-front-lines-of-covid-a-ceo-roundtable-on-technologies-in-development-for-the-current-pandemic-0001
$RLFTF (related) What's Happening On The Front Lines of COVID-19: A CEO Roundtable On Technologies In Development For The Current Pandemic
https://www.lifescienceleader.com/doc/what-s-happening-on-the-front-lines-of-covid-a-ceo-roundtable-on-technologies-in-development-for-the-current-pandemic-0001
..the letters R/S this early in the game are often used to inspire fear IMO
Fauci 'Depressed' U.S. Can't Get New Coronavirus Cases Down: 'We're Still in the First Surge'
http://a.msn.com/01/en-us/BB18VSlE?ocid=st
------
Coronavirus updates: Dr. Anthony Fauci says to 'hunker down' for the rest of the year; $300B relief bill fails in Senate; 191K US deaths
https://www.usatoday.com/story/news/health/2020/09/10/covid-19-news-senate-coronavirus-los-angeles-halloween-donald-trump/5761031002/ via @usatoday
..appropriate day for a huge Win for The Country.. 9/11 If RLF-100 can do what it's looking like it can do.. many lives will be saved and this Country can get back to work... was talking to someone last night and they mentioned cystic fibrosis .. Imagine if RLF-100 can help with that and other lung ailments.. Man!!
..nah, Jose Pozo would be loyal to the whole and stay where he's at IMO besides he does enough for many..
$RLFTF HAMMER TIME!! ..and that's the way it is...
Remember KODAK!!! There's no chart or data in the history of the stock exchange that can measure or predict what's going to happen when we get fda approval of a drug that can help change the outcome of this global war. Kodak was only approved of a loan to produce drug ingredients.
$GRLB Enjoy a sneak peak into our state-of-the-art CBD processing facility. From the farm, to the lab, to your hands; our CBD is carefully quality controlled to make sure you get the highest quality product possible.
video tweet 1 hr ago.. they're really getting professional and SAFE as a supplier.. IMO
Green Lotus Hemp
@GreenLotusHemp
https://twitter.com/GreenLotusHemp
Retweets help..
GL Brands on Twitter
https://twitter.com/glbrandsinc
https://twitter.com/greenlotushemp
https://twitter.com/iriecbd
https://twitter.com/iriehemp
$RLFTF Interesting thread:
might be a stretch but many new jobs posted today/ this wk with example
https://www.biospace.com/job/2169085/production-chemist-i-/
Develop peptide-manufacturing processes including peptide/protein purification by chromatography, crystallization, and other techniques, and in process test methods
Preferred:
Experience with Peptides
Receive, test and release final product peptide manufactured at Bachem
Test and release in-process control,
etc etc..
imo
----
Bachem who manufactures aviptadil for Relief is on a hiring spree. That is not a stretch at all. Sounds to me like someone is preping for a surge in production.
They are posting 67 jobs in Switzerland. The staff there is only 520 so that's a little over 12%. Pretty big...
https://www.jobs. ch/de/firmen/1351-bachem-ag/stellenangebote/
Also, glassdoor lists the job status as a "hiring surge"
https://www.glassdoor.com/Jobs/Bachem-Jobs-E244492.htm
Thanks for the heads up...
------
Seems like your onto something chap.
Here’s Bachems reference to Aviptadil on their website.
https://www.bachem.com/service-support/newsletter/peptide-trends-july-2019/
----
More evidence of what's coming soon! Thanks for that information
AP:9/9/2020 Once Mexico pulls the trigger on its new law, America will share borders with two countries allowed to produce legal cannabis on a wide scale.Canada and Mexico.
More importantly, they can export it to other countries that have legalized MMJ. At least 30 nations have legalized medical marijuana in some capacity. Mexican and Canadian (and Uruguayan) companies can send their products to countries like:
Germany
Czech Republic
Turkey
Poland
Argentina
Netherlands
Jamaica
Meanwhile, American cannabis firms continue to suffer legal and financial headaches.
While it will take years for the Mexican market to settle, there is a massive opportunity for prospective CBD firms.
At least, American CBD companies can ship their products internationally.
..don't need no Kramer anyhow.. we gots the goods!!
Yes I will wait for the FDA/Company to tell me RLF-100 is a cure.
Fauci: AstraZeneca pause in vaccine production 'not uncommon'
http://a.msn.com/01/en-us/BB18RoC7?ocid=st
$RLFTF Good outlook.. ;)
----
Re: (copy) it has been silent for quite some time; however, here are my thoughts and I'm sure many others on this board:
- No news, no pumping, likely indicates this is not a pump-n-dump and the professional, highly-connected leadership team is working through the FDA, political and big pharma landscapes.
- Hiring of a CMO and expanding trials into Europe indicates confidence in progress being made in the US and thus they are spending money to expand
- Preparing and publishing financials, website, pre-prints, partnerships, etc indicate a go-forward posture.
If these guys have a good product that will be approved by the FDA, they will become inundated with orders worldwide... its a massive effort behind the scenes that takes a while to come together. They already know what the results are, and if it were me running the show, I would not be pushing the FDA to hurry and approve, because we would not yet be in position to fulfill the need. Give these pros some time to pull the whole solution together; otherwise it could become a disaster with worldwide demand.
Disclaimer: I am not a professional advisor. Seek professional advice before investing or trading. I take risky positions and do not advise anyone to follow my opinions or actions.
Interesting post by bobbyleeswagger.. from ya-h oo
For NeuroRX to say..."We're committed to addressing this unmet need as quickly as possible."
This tells me that they have a viable product (they have the data and the trials went well), they are planning on bringing it to the market (manufacturing in place or being developed) and they are moving forward as quickly as possible (they are waiting for the FDA approval process to play out).
The ball is likely not in their court at the moment so they are waiting like all of us.
---
follow up reply: @BobbyLeeSwagger might not be a wise move to "pressure" the FDA by releasing any data.. i appreciate that they do this very professional. I rather see an approval at the end of a no-news period then news every day and no approval in the end. they are not just pumping their stock like our competition, rlftf does serios science, how it should be..
Scientists Cast Doubt on Results From Russian Covid Vaccine
http://a.msn.com/05/en-us/BB18PkOG?ocid=st
---
AstraZeneca pauses COVID-19 vaccine trial over possible adverse reaction in participant
https://www.cbsnews.com/news/covid-19-vaccine-trial-oxford-astrazeneca-pauses-participant-may-have-suffered-adverse-reaction/ via @CBSHealth
---
Biden and Harris ask Trump to 'publicly commit' to respecting science on a COVID-19 vaccine
http://a.msn.com/01/en-us/BB18PVml?ocid=st
Scientists Cast Doubt on Results From Russian Covid Vaccine
http://a.msn.com/05/en-us/BB18PkOG?ocid=st
---
AstraZeneca pauses COVID-19 vaccine trial over possible adverse reaction in participant
https://www.cbsnews.com/news/covid-19-vaccine-trial-oxford-astrazeneca-pauses-participant-may-have-suffered-adverse-reaction/ via @CBSHealth
---
Biden and Harris ask Trump to 'publicly commit' to respecting science on a COVID-19 vaccine
http://a.msn.com/01/en-us/BB18PVml?ocid=st